Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Total Non-Current Liabilities (2018 - 2025)

Historic Total Non-Current Liabilities for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $39.1 million.

  • Dna X's Total Non-Current Liabilities rose 2150.76% to $39.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.1 million, marking a year-over-year increase of 2150.76%. This contributed to the annual value of $43.7 million for FY2024, which is 3606.25% up from last year.
  • Latest data reveals that Dna X reported Total Non-Current Liabilities of $39.1 million as of Q3 2025, which was up 2150.76% from $35.7 million recorded in Q2 2025.
  • Dna X's Total Non-Current Liabilities' 5-year high stood at $43.7 million during Q4 2024, with a 5-year trough of $20.1 million in Q1 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $29.7 million (2023), whereas its average is $29.7 million.
  • In the last 5 years, Dna X's Total Non-Current Liabilities crashed by 2932.71% in 2024 and then skyrocketed by 6802.38% in 2025.
  • Over the past 5 years, Dna X's Total Non-Current Liabilities (Quarter) stood at $21.1 million in 2021, then skyrocketed by 53.02% to $32.2 million in 2022, then fell by 0.2% to $32.1 million in 2023, then skyrocketed by 36.06% to $43.7 million in 2024, then dropped by 10.59% to $39.1 million in 2025.
  • Its Total Non-Current Liabilities was $39.1 million in Q3 2025, compared to $35.7 million in Q2 2025 and $35.2 million in Q1 2025.